Company / PP&E (Net)
Ginkgo Bioworks Holdings, Inc. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$167.8M
FY2025
5-year range
$145.8M / $314.8M
FY2021-FY2025
Trend
-17.6%
vs FY2024
Sector context
#32 of 195
Health Care
What the data says
Ginkgo Bioworks Holdings, Inc.'s pp&e (net) of $168M is higher than 84% of companies in the Health Care sector (FY2025). PP&E (Net) has fluctuated over the past 6 years, ranging from $121M in FY2020 to $315M in FY2022.
Based on SEC 10-K filings.
$168M in FY2025 with a 5-year CAGR of +6.7%. Top quartile in the Health Care sector.
Declined from $188M to $168M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -18.9%
- 5-Year CAGR
- +6.7%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 195This company $167.8M Sector average $770.1M
▼
-78.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.7%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 17.6% year-over-year.
- Ranks #32 out of 195 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $167.8M | -17.6% |
| FY2024 | $203.7M | +8.3% |
| FY2023 | $188.2M | -40.2% |
| FY2022 | $314.8M | +115.9% |
| FY2021 | $145.8M | +20.0% |
| FY2020 | $121.4M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026